Ustekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseBrian G. Feagan, Paul Rutgeerts, William J. Sandborn et al.|New England Journal of Medicine|2016Cited by 1.8k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's DiseaseWilliam J. Sandborn, Brian G. Feagan, Christopher Gasink et al.|New England Journal of Medicine|2012Cited by 1.1k
A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's DiseaseWilliam J. Sandborn, Paul Rutgeerts, Brian G. Feagan et al.|Gastroenterology|2008Cited by 750
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic ResectionMiguel Regueiro, Pierre Desreumaux, Naoki Chiba et al.|Gastroenterology|2016Cited by 335
Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative ColitisJeffrey S. Hyams, Anne M. Griffiths, Lakshmi Damaraju et al.|Clinical Gastroenterology and Hepatology|2011Cited by 284